Last updated: February 22, 2022
Sponsor: OptiSkin Medical
Overall Status: Active - Recruiting
Phase
4
Condition
Atopic Dermatitis
Allergy
Allergies & Asthma
Treatment
N/AClinical Study ID
NCT05265234
OPTI-003
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- ≥18 years of age
- Atopic dermatitis (AD) affecting ≥10% body surface area (BSA) at baseline
- IGA score ≥3, on the IGA scale of 0-4 at baseline
- Eczema Area and Severity Index (EASI) score of ≥16 at baseline
Exclusion
Exclusion Criteria:
- Prior treatment with Dupilumab (REGN668/SAR231893)
- Treatment with TCS or topical calcineurin inhibitors (TCI) within 2 weeks before thebaseline visit
- Bodyweight <30 kg (65lb) at Baseline
- Known or suspected immunodeficiency including human immunodeficiency virus (HIV)infection
- Pregnancy, breastfeeding or planning to become pregnant or breastfeed during the study
Study Design
Total Participants: 15
Study Start date:
March 01, 2022
Estimated Completion Date:
March 01, 2024
Study Description
Connect with a study center
OptiSkin Medical
New York, New York 10128
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.